Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the effect of HuMax-CD4 as a treatment for early
stage cutaneous T-cell lymphoma (CTCL). Almost all patients who are affected by CTCL have
cancerous cells which bear a receptor called CD4. HuMax-CD4 is an investigational drug
directed against this receptor. There is no placebo in this trial; all patients will be
treated with HuMax-CD4. During the trial, the response rates, duration of responses, relief
of symptoms, and safety profile of HuMax-CD4 will be evaluated.